Clinical study of BACOD regimen of relapsed and refractory non-Hodgkin lymphoma

VernacularTitle:BACOD方案治疗复发及难治性非霍奇金淋巴瘤的临床研究
Author: Jianwei DU ; Yufu LI ; Huizhen MA ; Xinghu ZHU ; Xudong WEI ; Yongping SONG
Publication Type:Journal Article
Keywords: Lymphoma,non-Hodgkin's; Recurrencei; Drug therapy,combination; Refractory; BCOAD regimen
From: Journal of Leukemia & Lymphoma 2010;19(8):492-493,496
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and adverse events of BACOD regimen for relapsed and refractory non-Hodgkin lymphoma (NHL). Methods Sixty patients with relapsed and refractory NHL received chemotherapy of BACOD regimen: bleomycin 10 mg/m2, intravenous drip on the 2nd and 9th day;cyclophosphamide 750 mg/m2, intravenous drip on 1st day; vindesine 3 mg/m2, intravenous drip on 1st and 8th day; cytarabine 150 mg/m2, intravenous drip on 2nd-5th days; dexamethasone 10 mg/m2, intravenous drip on 2nd-5th days; every 3 weeks was one cycle. Results Eighteen cases (27.7 %) received the complete remission (CR), 30 the partial remission (PR), 13 stable disease (SD) and 4 progressive disease (PD). The overall response (CR+PR) rate was 70.8 %. The median remission time of patients with response was 11 months(2-38 months). The 1-year survival rate was 32.3 % and the 2-year survival rate was 24.6 %. The main adverse events were myelosuppression. Conclusion BACOD regimen can be used as the relief regimen of relapsed and refractory NHL.